TXN and acute lymphoblastic leukemia: Finally, we showed that pharmacological inhibition of the thioredoxin system by the chemotherapeutic drug arsenic trioxide (ATO) enhanced MTX cytotoxicity in vivo against one out of four primary human ALL cells, suggesting a novel therapeutic rationale to be further explored against ALL.